Antibacterial Drug Development
an FDA Perspective

Ed Cox, MD MPH
Director, Office of Antimicrobial Products
OND/CDER/FDA
Background

• Development of new antibacterial agents is essential to meet patient needs
  – Need therapies to treat patients with infections today
  – Know we will need new options in the future

• Two development prongs - ideally
  – Unmet need – trying to catch up to meet critical public health needs in areas where we are behind
  – Ongoing development – so new options are available to address the needs that we know will arise in the years ahead
Challenges in Studying Antibacterial Drugs

• Biology of the acute bacterial infectious diseases
  - Acute illness - Early doses important
  - Urgent need to initiate therapy for serious infections
  - Diagnostic uncertainty
  - Micro diagnosis – time delayed – detection limits of common techniques – better diagnostics could help
  - Effects of prior therapy or concomitant therapy – may cloud assessment of the test drug (NI trials)
  - Heterogeneity in outcomes dependent upon multiple factors (e.g., patient factors)

• Limitations of the available information on natural history of disease to estimate treatment effect

• Different compared to many other therapeutic areas
Antibacterial Drug Development

• Extent and breadth of antibacterial drug development seems below level needed to meet patient needs
• Limited development activity in some therapeutic indications
• Balancing precision of assessments of safety and efficacy with feasibility & public health need for new options – areas of unmet need
• Tools & approaches to facilitate study of new antibacterial drugs
Unmet Need

• Serious or life-threatening bacterial infections where patients lack satisfactory therapeutic options
• Risk / Benefit in the setting of unmet need
• More streamlined development – get drugs to patients sooner in areas of unmet need
• Greater uncertainty / risk with a more limited development program
• An indication that reflects the more limited development program – targeting use in settings where other available drugs not satisfactory
Unmet Need – Data Sources

• Preclinical Data – what role can this data contribute?
  – Mechanism of action / impact of resistance to other drugs
  – Animal models of infection

• Clinical Data
  – PK data to estimate appropriate dosing in indicated population(s)
  – Data from a trial in patients with serious or life-threatening infections (role of patients with “susceptible” infections)
    • Approaches to analyzing data from across multiple body sites
    • Clinical trial may enroll patients with organisms resistant to other therapies and patients with organisms susceptible to other therapies
    • Degree of precision of estimates of safety and efficacy if indication is for patients who lack satisfactory treatment options
  – Additional data from limited experience in patients with limited therapeutic options b/c of “resistant” organisms
Tools

- Better means to evaluate safety and efficacy
- Can we learn more from the data that is accrued during development?
- Can Bayesian approaches help?
- Approaches to analyzing data in a trial enrolling patients with infections from across multiple body sites
- Can endpoints be further developed and standardized to facilitate and enrich development?
- Are there clinical trials procedures that are being done that do not add value?
- Can clinical trial networks facilitate the study of antibacterial drugs given the inherent challenges in studying antibacterial drugs for these acute diseases
Thank you